Identification | Back Directory | [Name]
(2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide | [CAS]
133865-88-0 | [Synonyms]
Nw-1029 FCE-26742A ralfinamide Ralfinamida Safinamide-6 Priralfinamide Unii-3lpf0S0gvv Ralfinamide [inn] Guadecitabine Sodium Safinamide Impurity 12 Ralfinamida [inn-spanish] (2S)-2-(4-(2-Fluorobenzyloxy)benzylamino)propanamide (S)-2-[[4-[(2-Fluorobenzyl)oxy]benzyl]amino]propanamide (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide Propanamide, 2-[[[4-[(2-fluorophenyl)methoxy]phenyl]methyl]amino]-, (2S)- Safinamide impurity 3/(S)-2-((4-((2-fluorobenzyl)oxy)benzyl)amino)propanamide (2S)-2-[[4-[(2-fluorophenyl)methoxy]phenyl]methylamino]propanamide/Safinamide Impurity | [EINECS(EC#)]
200-582-5 | [Molecular Formula]
C17H19FN2O2 | [MDL Number]
MFCD08272558 | [MOL File]
133865-88-0.mol | [Molecular Weight]
302.34 |
Chemical Properties | Back Directory | [Boiling point ]
479.0±40.0 °C(Predicted) | [density ]
1.189 | [storage temp. ]
Keep in dark place,Sealed in dry,2-8°C | [solubility ]
DMSO: ≥ 125 mg/mL (413.44 mM) | [form ]
Solid | [pka]
16.03±0.50(Predicted) | [color ]
White to off-white |
Hazard Information | Back Directory | [Uses]
Ralfinamide (FCE-26742A) is an orally available Na+ blocker derived from α-aminoamide, with function of suppressing pain[1][2]. | [Biological Activity]
Ralfinamide (FCE-26742A) is an orally available sodium channel blocker derived from α-aminoamide with analgesic properties. | [in vivo]
Ralfinamide (30 mg/kg, 60 mg/kg; p.o.; twice daily; 42 days) treated with Ralfinamide (80 mg/kg; p.o.; twice daily; 7 days) preoperatively suppresses neuropathic pain[1].
Animal Model: | 81 adult male Sprague–Dawley male rats (260–460 g)[1] | Dosage: | 80 mg/kg (7 days preoperatively), 30 mg/kg, 60 mg/kg (postoperative) | Administration: | Oral gavage; twice daily; until postoperative day 42 | Result: | Suppressed neuropathic pain. |
| [storage]
Store at -20°C | [References]
[1] Zhang SH, et al. Ralfinamide administered orally before hindpaw neurectomy or postoperatively provided long-lasting suppression of spontaneous neuropathic pain-related behavior in the rat. Pain. 2008 Oct 15;139(2):293-305. DOI:10.1016/j.pain.2008.04.020 [2] Liang X, et al. Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. Eur J Pharmacol. 2018 Mar 15;823:27-34. DOI:10.1016/j.ejphar.2018.01.041 |
|
|